Aim: To confirm whether exosome-mediated delivery of aptamer S58 (Exo-S58) has a better antifibrotic effect than naked S58 in human conjunctival fibroblasts (HConFs) and a rat glaucoma filtration surgery (GFS) model.
Methods: To enhance the effective reaction time of aptamer S58 , we loaded aptamer S58 into exosomes derived from HEK293T cells by PEI transfection to determine the effect of Exo-S58 in HConFs and a rat GFS model.
Results: Exo-S58 can significantly reduce cell proliferation, migration and fibrosis in TGF-β2-induced HConFs. In an experiment, Exo-S58 treatment prolonged filtering bleb retention and reduced fibrosis compared with naked S58 treatment in GFS rats.
Conclusion: The exosomes are safe and valid carriers to deliver aptamers. Furthermore, Exo-S58 exhibited superior antifibrotic effect than naked S58 both in HConFs cells and rat GFS models.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9091888 | PMC |
| http://dx.doi.org/10.18240/ijo.2022.05.02 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Discovery of Aptamers and the Acceleration of the Development of Targeting Research in Ophthalmology.
Int J Nanomedicine
August 2023
Department of Ophthalmology, Third Xiangya Hospital, Central South University, Changsha, People's Republic of China.
Article Synopsis
- Aptamers are short DNA or RNA molecules that are effective in targeting specific proteins, making them valuable for diagnosing and treating eye disorders, though research in this area is still emerging.
- Recent studies have evaluated aptamer-related drugs, like pegaptanib and others, that target factors such as TGF-β and VEGF to prevent complications in conditions like glaucoma and age-related macular degeneration.
- This review highlights the ongoing development of aptamers for both early diagnosis and therapy of various eye disorders, suggesting their potential to improve understanding and treatment strategies for these conditions.
Exosome-mediated aptamer S58 reduces fibrosis in a rat glaucoma filtration surgery model.
Int J Ophthalmol
May 2022
Department of Ophthalmology, The Third Affiliated Hospital of Chongqing Medical University, Chongqing 401120, China.
Aim: To confirm whether exosome-mediated delivery of aptamer S58 (Exo-S58) has a better antifibrotic effect than naked S58 in human conjunctival fibroblasts (HConFs) and a rat glaucoma filtration surgery (GFS) model.
Methods: To enhance the effective reaction time of aptamer S58 , we loaded aptamer S58 into exosomes derived from HEK293T cells by PEI transfection to determine the effect of Exo-S58 in HConFs and a rat GFS model.
Results: Exo-S58 can significantly reduce cell proliferation, migration and fibrosis in TGF-β2-induced HConFs.
The TβR II-targeted aptamer S58 prevents fibrosis after glaucoma filtration surgery.
Aging (Albany NY)
May 2020
Department of Ophthalmology, The Third Affiliated Hospital of Chongqing Medical University (Gener Hospital), Chongqing 401120, China.
Glaucoma filtration surgery (GFS) is an effective clinical treatment for glaucoma when intraocular pressure (IOP) control is poor. However, the occurrence of conjunctival scarring at the surgical site is the main reason for failure of the surgery. In a previous study, we isolated and developed S58, a novel nucleic acid aptamer targeting TβR II, by systematic evolution of ligands by exponential enrichment (SELEX).
View Article and Find Full Text PDFEvaluation of Chitosan/Aptamer Targeting TGF-β Receptor II Thermo-Sensitive Gel for Scarring in Rat Glaucoma Filtration Surgery.
Invest Ophthalmol Vis Sci
August 2015
Department of Ophthalmology Institute of Surgery Research, Daping Hospital, Third Military Medical University, Chongqing, People's Republic of China.
Purpose: This study was designed to develop a chitosan (CS) thermo-sensitive gel combined with aptamer S58 targeting transforming growth factor-beta receptor II (TGF-β RII) and to investigate the antifibrotic effects of CS/S58 gel in a rat glaucoma filtration surgery (GFS) model.
Methods: In vitro aptamer S58 release rate from the CS/S58 gel were detected, and the effect of mitomycin-C (MMC), TGF-β2, CS, or CS/S58 gel on wound healing were investigated in a rat GFS model by detecting scar-related factors and the involved inflammatory response. The levels of collagen I and α-smooth muscle actin (α-SMA) were detected by immunohistochemistry and Western blotting.
Investigation on novel chitosan nanoparticle-aptamer complexes targeting TGF-β receptor II.
Int J Pharm
November 2013
Department of Ophthalmology, Daping Hospital & Research Institute of Surgery, Third Military Medical University, Chongqing, China.
In our previous study, a dominant sequence called aptamer S58 antagonized TGF-β-induced myofibroblast transdifferentiation in human Tenon's capsule fibroblasts (HTFs) through sealing the targeting site of TGF-β receptor II (TβR II). However, rapid degradation by ubiquitous nucleases limited the aptamer's efficacy. Chitosan-nanoparticles (CS-NP) are good drug carriers.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!